Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart Failure - An Investigator-initiated, Event-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial Without Investigational Medical Products (Proof of Strategy Trial)

NCT03494933 is registered in ClinicalTrials.gov with Helios Health Institute GmbH as lead sponsor.

NCT NCT03494933
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03494933 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Re-evaluation of Optimal Re-synchronisation Therapy in Patients With Chronic Heart Failure - An Investigator-initiated, Event-driven, Prospective, Parallel-group, Randomised, Open, Blinded Outcome Assessment (PROBE), Multi-centre Trial Without Investigational Medical Products (Proof of Strategy Trial)
Lead sponsor
Helios Health Institute GmbH
Phase
Not applicable
Overall status
Terminated
Start date
September 1, 2018
Completion date
February 21, 2023
Enrollment
959 (actual)
Sites
113

Conditions

As the registry lists them; a condition with its own page is linked.

chronic heart failure